Preventing diabetic retinopathy through control of systemic factors

Current Opinion in Ophthalmology

Volumn 14, Issue 6, 2003, Pages 389-394

  Jain, Atul ^a   Sarraf, David ^b,c,d   Fong, Donald ^a,b,e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

^c West Los Angeles Veteran's Administration Hospital   (United States)

^d CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

^f NONE   (United States)

Author keywords

Aspirin; Diabetic retinopathy; Genetic; Hyperglycemia; Hypertension; Serum lipids; Smoking; Systemic control

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NISOLDIPINE;

ANTICOAGULATION; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DYSLIPIDEMIA; EXUDATE; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA MACULOPATHY; REVIEW; RISK; RISK FACTOR; TREATMENT INDICATION; VISUAL IMPAIRMENT;

ANTICOAGULANTS; ASPIRIN; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY DISEASES; PREGNANCY; PREGNANCY IN DIABETICS;

EID: 1542616633     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200312000-00012     Document Type: Review

References (55)

1. American Diabetes Association Web site: Available at: http://www.diabetes.org
2. Klein R, Klein BEK, Moss SE, et al.: The Wisconsin epidemiologic study of diabetic retinopathy, III: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984a, 102:520-526.
3. Klein R, Klein BEK, Moss SE, et al.: The Wisconsin epidemiologic study of diabetic retinopathy, III: prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984b, 102:527-532.
4. Klein R, Klein BEK, Moss SE, et al.: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. J Am Med Assoc 1988, 260:2864-2871.
5. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
6. The Diabetes Control and Complications Trial Research Group: Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology 1995, 102:647-661.
7. The United Kingdom Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. United Kingdom Prospective Diabetes Study Report Number 33. Lancet 1998, 352:837-853.
8. The Diabetes Control and Complications Trial/Epidemiology of Diabetes and Complications Research Group: Retinopathy and nephropathy in patients with type I diabetes four years after a trail of intensive therapy. N Engl J Med 2000, 342:381-389.
9. Van Leiden HA, Dekker JM, Moll AC, et al.: Risk factors for incident retinopathy in a diabetic and nondiabetic population: The Hoorn study. Arch Ophthalmol 2003, 121:245-251. The most recent descriptive study that evaluates the effects of glycemic status, hypertension, dyslipidemia, obesity, and smoking as risk factors in both diabetic and nondiabetic populations over a 10-year follow-up period.
10. The United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. United Kingdom Prospective Diabetes Study Report Number 38. BMJ 1998, 317:703-713.
11. Aiello LP, Cahill MT, Wong JS: Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001, 132:760-776.
12. The United Kingdom Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. United Kingdom Prospective Diabetes Study Report Number 39. BMJ 1998, 317:713-720.
13. Estacio RO, Jeffers BW, Gifford N, et al.: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23:B54-B64.
14. Klein R, Klein BEK: Blood pressure control and diabetic retinopathy. Br J Ophthalmol 2002, 86:365-367.
15. Sjolie AK, Chaturvedi N, Fuller J: Effect of lisinopril on progression of retinopathy and microalbuminuria in normotensive subjects with insulin-dependent diabetes mellitus. Ugeskr Laeger 1999, 161:949-952.
16. The Microalbuminuria Collaborative Study Group: Predictors of the development of microalbuminuria in patients with type I diabetes mellitus. A seven-year prospective study. Diabet Med 1999, 16:918-925.
17. Klein R, Klein BEK, Moss SE, et al.: The Wisconsin epidemiologic study of diabetic retinopathy: V. Proteinuria and retinopathy in a population of diabetic persons diagnosed prior to 30 years of age. In Diabetic Renal-Retinal Syndrome 3. Edited by Freidman EA, L'Esperance FA. Orlando: Grune & Stratton; 1986.
18. Mathiesen ER, Ronn B, Storm B, et al.: The natural course of microalbuminuria in insulin-dependent diabetes: a 10 year prospective study. Diabet Med 1995, 12:482-487.
19. Klein R, Klein BEK, Moss SE, et al.: The wisconsin epidemiologic study of diabetic retinopathy, XVII: the 14 year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology 1998, 105:1801-1815.
20. Pradhan R, Fong D, March C, et al.: Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients: A pilot study. J Diabetes Complications 2002, 16:377-381. A recent study that found little, if any, role for the use of ACE inhibitors over β-blockers in the treatment of moderate to severe DR in type 2 diabetics.
21. Hogeboom van Buggenum IM, Polak BCP, Reichert-Thoen JWM, et al.: Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002, 45:203-209.
22. Chaturvedi N, Fuller JH, Pokrst F, et al.: Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 2001, 18:288-294.
23. Charurvedi N, Sjolie AK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998, 351:28-31.
24. Chase HP, Garg SK, Harris S, et al.: Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993, 25:284-289.
25. Larsen M, Hommel E, Parving HH, et al.: Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990, 228:505-509.
26. Ravid M, Brosh D, Ravid-Safran D, et al.: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998, 158:998-1004.
27. Chowdhury TA, Hopkins D, Dodson PM, et al.: The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye 2002, 16:689-693. A brief review of the role of serum lipids in diabetic maculopathy, including the data and rationale behind further studies looking at the effects of lipid-lowering agents on retinal exudates.
28. Harold M, Marmion VJ, Gough KR: A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969, 84:285-291.
29. Cullen JF, Ireland JT, Oliver MF: A controlled trial of atromid therapy in exudative diabetic retinopathy. Trans Ophthalmol Soc U K 1964, 84:281-295.
30. Duncan LJ, Cullen JF, Ireland JT: A three-year trial atromid therapy in exudative diabetic retinopathy. Diabetes 1968, 17:458-467.
31. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996, 114:1079-1084.
32. Fong DS, Segal PP, Myers F, et al.: Subretinal fibrosis in diabetic macular edema. EDTRS report 23. Arch Ophthalmol 1997, 115:873-877.
33. Bergerhoff K, Clar C, Richter B: Aspirin in diabetic retinopathy: a systematic review. Endocrinol Metab Clin North Am 2002, 31:779-793. A metaanalysis of all studies cor cerning aspirin use in DR. There are no ocular contraindications to the use of aspirin therapy for other medical indications in the patient with DR.
34. Kern TS, Engerman RL: Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001, 50:1636-1641.
35. Effects of aspirin treatment on diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 8. Ophthalmology 1991, 98:757-765.
36. Moss SE, Klein R, Klein BE: Cigarette smoking and the ten-year progression of diabetic retinopathy. Ophthalmology 1996, 103:1432-1442.
37. Muhlhauser I, Bender R, Bott U, et al.: Cigarette smoking and progression of retinopathy and nephropathy in type I diabetics. Diabet Med 1996, 13:536-543.
38. Magrini A, Bottini N, Nicotra M, et al.: Smoking and the genetics of signal transduction: an association study on retinopathy in type 1 diabetics. Am J Med Sci 2002, 324:310-313.
39. Moss SE, Klein R, Klein BEK: Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996, 103:1438-1442.
40. Moloney JB, Drury MI: The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol 1982, 93:745-756.
41. Klein BEK, Moss SE, Klein R: Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990, 13:34-40.
42. The Diabetes Control and Complications Trial Research Group: The effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care 2000, 23:1084-1091.
43. Loukovaara S, Harju M, Kaaja R, et al.: Retinal capillary blood flow in diabetic and nondiabetic women during pregnancy and postpartum period. Invest Ophthalmol Vis Sci 2003, 41:1486-1491. Direct measurement of retinal capillary blood flow during pregnancy revealed increased blood flow both during and after pregnancy in diabetic women; this hyperdynamic blood flow may contribute of the progression of DR in pregnancy.
44. Chen HC, Newsom RS, Patel V, et al.: Retinal blood flow changes during pregnancy in women with diabetes. Invest Ophthalmol Vis Sci 1994, 35:3199-3208.
45. Schocket LS, Grunwald JE, Tsang AF, et al.: The effect of pregnancy on retinal hemodynamics in diabetic versus nondiabetic mothers. Am J Ophthalmol 1999, 128:477-484.
46. Shone H, Okuda Y, Kawakami Y, et al.: Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture. Life Sci 1996, 59:21-25.
47. Chew EY, Mills JL, Metzger BE, et al.: Metabolic control and progression of retinopathy. The diabetes in early pregnancy study. National institute on child health and human development diabetes in early pregnancy study. Diabetes Care 1995, 18:631-637.
48. Sheth BP: Does pregnancy accelerate the rate of progression of diabetic retinopathy? Curr Diab Rep 2002, 2:327-330.
49. Loukovaara S, Immonen I, Teramo KA, et al.: Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 2003, 26:1193-1198. A prospective studying showing that treatment of diabetic women during pregnancy with insulin lispro improved glycemic control compared with regular insulin.
50. Chaturvedi N, Stephensom JM, Fuller JH: The relationship between pregnancy and long-term maternal complications in the EURODIAM IDDM Complications Study. Diabet Med 1995, 12:494-499.
51. Rema M, Saravanan G, Deepa R, Mohan V: Familial clustering of diabetic retinopathy in south Indian type 2 diabetic patients. Diabet Med 2002, 19:910-916.
52. Quiroz-Mercado H, Suárez-Licona A, Fromow-Guerra J, et al.: Human lymphocyte antigen DR7 protects against proliferative retinopathy with type II diabetes mellitus. Arch Med Res 2002, 33:123-127.
53. Radha V, Rema M, Mohan V: Genes and diabetic retinopathy. Indian J Ophthalmol 2002, 50:5-11. An excellent review of the genetic factors most likely to be involved in the development of diabetic retinopathy.
54. Kamiuchi K, Hasegawa G, Obayashi H, et al.: Intercellular adhesion molecule-1 (ICAM-1) polymorphism is associated with diabetic retinopathy in type 2 diabetes mellitus. Diabet Med 2002, 19:371-376.
55. 1) is a newly identified risk factor for proliferative diabetic retinopathy. Am J Med Genet 2002, 109:278-283.